MedTrace Logo

Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment

NCT00717990 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2015-10-07

No results posted yet for this study

Summary

This study will evaluate the efficacy of Irinotecan,Capecitabine and Avastin combination in patients with no response to previous treatment with 5-Fluorouracil,Leucovorin,Eloxatin and Avastin.

Conditions

Interventions

DRUG

Capecitabine

Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles

DRUG

Bevacizumab

Bevacizumab 7.5 mg/kg intravenous (IV) on day 1 every 3 weeks for 6 cycles

DRUG

Irinotecan

Irinotecan 250 mg/m2 IV on day 1 every 3 weeks for 6 cycles

Sponsors & Collaborators

  • University Hospital of Crete

    lead OTHER

Principal Investigators

  • Vassilis Georgoulias, MD · University Hospital of Crete, Dep of Medical Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00717990 on ClinicalTrials.gov